NICE’s Approval of Marstacimab for Hemoph...

By João L. Carapinha

May 30, 2025

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending marstacimab hemophilia B (Hympavzi®), a novel subcutaneous monoclonal antibody, for prophylaxis in severe hemophilia B but not for hemophilia...
Alzheimer’s Blood Test Diagnostics: FDA Clears First Blood Test for Ear...
EMA AI Tool Qualification: How the AIM-NASH Approval Sets a Roadmap for Medic...
VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options
First At-Home HPV Testing Approval: FDA Clears Teal Wand
MR-107A-02: Revolutionizing Non-Opioid Pain Management with Viatris’ Breakthr...
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel
TAVR Asymptomatic Approval: A New Era for Early Intervention in Aortic Stenosis
Ivonescimab NMPA Approval Signals Breakthrough in Lung Cancer
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...
Nipocalimab for Myasthenia Gravis Treatment
Trodelvy Keytruda Combination Delivers Breakthrough Results in Metastatic Tri...